Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers

Modern Rheumatology

Volumn 19, Issue 2, 2009, Pages 216-218

  Nii, Tokiko ^a   Kubota, Tetsuo ^a   Nanki, Toshihiro ^a   Komano, Yukiko ^a   Harigai, Masayoshi ^a   Kohsaka, Hitoshi ^a   Hirose, Wataru ^b   Nagasaka, Kenji ^c   Sakurai, Tetsushi ^d   Miyasaka, Nobuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Hirose Clinic   (Japan)

^c Ome Municipal General Hospital   (Japan)

^d Sakurai Clinic   (Japan)

Author keywords

Etanercept; Infliximab; Influenza vaccine; Survival of plasma cells

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPSTEIN BARR VIRUS ANTIGEN; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY TITER; ARTICLE; DISEASE ACTIVITY; EPSTEIN BARR VIRUS; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOFLUORESCENCE TEST; INFLUENZA; INFLUENZA VACCINATION; MEASLES VIRUS; MUMPS VIRUS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VIRUS STRAIN;

ANTIBODIES, VIRAL; ARTHRITIS, RHEUMATOID; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; JAPAN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64549097545     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0135-z     Document Type: Article

References (9)

1. Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:531-3.
2. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNFα blockers. Ann Rheum Dis. 2006;65:191-4.
3. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272-9.
4. Kapetanovic MC, Saxne T, Nilsson J-Å, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology. 2007;46:608-11.
5. Gelinck LBS, van der Bijl AE, Beyer WEP, Visser LG, Huizinga TWJ, van Hogezand RA, et al. The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67:713-6.
6. Lee C-K, Lee EY, Chung SM, Mun SH, Yoo B, Moon H-B. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand. Arthritis Rheum. 2004;50:3831-43.
7. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis. 2008;67:296-301.
8. Geffroy-Luseau A, Jégo G, Bataille R, Campion L, Pellat-Deceunynck C. Osteoclasts support the survival of human plasma cells in vitro. Int Immunol. 2008;20:775-82.
9. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner ECB, et al. Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol. 2008;180:688-92.